Disclosed are charged lipoprotein complexes that include a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties. An apolipoprotein fraction and a lipid fraction, said lipid fraction consisting essentially of 0.2 to 3 wt% of one or 5 more negatively charged phospholipids, sphingomyelin, and lecithin.